Stock 471A ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Market Closed - Deutsche Boerse AG
Other stock markets
 02:14:27 2024-05-31 EDT 		5-day change 1st Jan Change
1.59 EUR +4.61% Intraday chart for aTyr Pharma, Inc. -2.45% +23.26%
05-14 ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis CI
05-02 ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis
ATyr Pharma to Present at Upcoming Investor Conferences
Atyr Pharma: Q1 Earnings Snapshot
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
ATyr Pharma to Participate in April Investor Conferences
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Atyr Pharma: Q4 Earnings Snapshot
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. 471A Stock
  5. News aTyr Pharma, Inc.
  6. Other languages